A Phase I Pharmacokinetics and Pharmacodynamic Study of GTI2040 in Combination With Gemcitabine in Patients With Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose (MTD) of GTI-2040 and gemcitabine hydrochloride, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v3.0
研究概览
简要总结
This phase I trial is studying the side effects and best dose of GTI-2040 and gemcitabine in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. GTI-2040 may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by making tumor cells more sensitive to gemcitabine
详细描述
OBJECTIVES: Primary I. Determine the toxicity profile and maximum tolerated dose of GTI-2040 and gemcitabine in patients with metastatic or unresectable solid tumors.
Secondary I. Determine the pharmacokinetics and pharmacodynamics of this regimen in these patients.
OUTLINE: This is an open-label, dose-escalation study.
Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed solid tumor
- •Metastatic or unresectable disease for which standard curative or palliative measures do not exist or are no longer effective
- •Measurable or evaluable disease
- •No known active or progressive brain metastases or primary brain tumors
- •Performance status - ECOG 0-2
- •Performance status - Karnofsky 60-100%
- •More than 12 weeks
- •Hemoglobin > 9 g/dL
- •Absolute neutrophil count ≥ 1,500/mm^3
- •Platelet count ≥ 100,000/mm^3
- •Bilirubin ≤ 2 times upper limit of normal (ULN)
- •AST and ALT ≤ 3 times ULN (5 times ULN if hepatic metastases are present)
- •Creatinine ≤ 2.0 mg/dL
- •Creatinine clearance ≥ 50 mL/min
- •No symptomatic congestive heart failure
- •No unstable angina pectoris
- •No cardiac arrhythmia
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No prior allergic reaction attributed to compounds of similar chemical or biological composition to study drugs
- •No ongoing or active infection
- •No psychiatric illness or social situation that would preclude study compliance
- •No other condition (e.g., dementia or developmental delay) that would preclude giving informed consent
- •No other concurrent uncontrolled illness that would preclude study participation
- •Prior biologic therapy allowed
- •No concurrent biologic therapy
- •No concurrent immunotherapy
- •No concurrent routine filgrastim (G-CSF) or sargramostim (GM-CSF)
- •Prior gemcitabine allowed
- •Prior investigational chemotherapy allowed
- •At least 4 weeks since prior chemotherapy (6 weeks for mitomycin, carmustine, or nitrosoureas) and recovered
- •No other concurrent chemotherapy
- •Concurrent hormonal therapy (e.g., luteinizing hormone-releasing hormone agonists) for prostate cancer is allowed
- •At least 4 weeks since prior radiotherapy and recovered
- •No prior radiotherapy to more than 25% of bone marrow
- •No concurrent radiotherapy
- •Recovered from prior surgery
- •No other concurrent investigational therapy
- •No other concurrent anticancer therapy
- •No concurrent combination antiretroviral therapy for HIV-positive patients
- •No concurrent long-term oral anticoagulation therapy (e.g., warfarin)
- •Prophylactic warfarin to maintain central venous access patency allowed
排除标准
- 未提供
研究组 & 干预措施
Treatment (GTI-2040, gemcitabine hydrochloride)
Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose.
干预措施: GTI-2040 (Biological)
Treatment (GTI-2040, gemcitabine hydrochloride)
Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose.
干预措施: gemcitabine hydrochloride (Drug)
Treatment (GTI-2040, gemcitabine hydrochloride)
Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose.
干预措施: laboratory biomarker analysis (Other)
Treatment (GTI-2040, gemcitabine hydrochloride)
Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose.
干预措施: pharmacological study (Other)
结局指标
主要结局
Maximum tolerated dose (MTD) of GTI-2040 and gemcitabine hydrochloride, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v3.0
时间窗: Up to day 28
Adverse events, graded according to the NCI CTC v3.0
时间窗: Up to 2 years
次要结局
- Levels of gemcitabine triphosphate (dFdCTP) in terms of pharmacokinetics of gemcitabine hydrochloride(Days 1, 2, 8, and 15 (course 1), days 1, 2, 9, and 16 (course 2))
- Levels of ribonucleotide reductase R2 and protein expression(Days 1, 2, 8, and 15 (course 1), days 1, 2, 9, and 16 (course 2))
- Levels of apoptotic markers and cell cycle regulatory proteins(Days 1, 2, 8, and 15 (course 1), days 1, 2, 9, and 16 (course 2))